The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia

Published:2024-08-18 Issue: Volume: Page:1-9
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ngo Dat¹,Tinajero Jose¹,Song Joo Y.²,Ma Huiyan³,Quirk Elizabeth²,Koller Paul⁴,Pourhassan Hoda⁴^ORCID,Agrawal Vaibhav⁴,Stein Anthony S.⁴,Marcucci Guido⁴,Murphy Lindsey⁵^ORCID,Forman Stephen J.⁴,Pullarkat Vinod⁴,Aldoss Ibrahim⁴

Affiliation:

1. Department of Pharmacy, City of Hope, Duarte, CA, USA

2. Department of Pathology, Division of Hematopathology, City of Hope, Duarte, CA, USA

3. Department of Computational and Quantitative Medicine, Division of Health Analytics, City of Hope, Duarte, CA, USA

4. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA

5. Department of Pediatrics, City of Hope, Duarte, CA, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2392823

Reference13 articles.

1. Toward victory in adult ALL: blinatumomab joins in

2. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

3. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

4. Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

5. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia